According to filings with the U.S. Securities and Exchange Commission, Aer Therapeutics is raising $36,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, James Shaffer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aer Therapeutics
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on treating respiratory diseases with significant unmet need, such as COPD, cystic fibrosis and asthma. Our technology was developed and spun out of Dr. John Fahys airway biology lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarsons glycochemistry lab at University College Dublin and Dr. Anne Marie Healys pharmaceutics lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.

To learn more about Aer Therapeutics, visit http://aertherapeutics.com/

Contact:
James Shaffer, Chief Executive Officer
919-345-4256

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.